Affymetrix and Iconix Collaborate to Develop New Solutions for Assessing Drug Toxicity
Advertisement
Affymetrix Inc. and Iconix Pharmaceuticals Inc. announced that the companies have signed a collaborative agreement to develop solutions to aid in the study of the toxicological and pharmacological properties of drugs and drug candidates. The collaboration will aim to significantly accelerate the drug development process by combining Affymetrix' microarray technology with Iconix' compound reference database and analysis software.
Together, Affymetrix' expression arrays and Iconix' analysis methods will provide detailed information on a drug candidate's toxicological liabilities and pharmacological properties. Using such tools, researchers will be able to quickly compare gene expression profiles to the Iconix' Drug Signatures(R) library to help predict the impact that gene expression changes may have on biological pathways critical to the body's toxic response to drugs.
Most read news
Organizations
Other news from the department business & finance
These products might interest you

OMNIS-Software by Metrohm
Efficient Lab Workflows Through Intelligent Data Management
Central Data Management with an Intuitive User Interface for the Highest Compliance Standards

Limsophy by AAC Infotray
Optimise your laboratory processes with Limsophy LIMS
Seamless integration and process optimisation in laboratory data management

LAUDA.LIVE by LAUDA
LAUDA.LIVE - The digital platform for your device management
Comprehensive fleet management options for every LAUDA device - with and without IoT connectivity

ERP-Software GUS-OS Suite by GUS
Holistic ERP solution for companies in the process industry
Integrate all departments for seamless collaboration

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

BASF and Karlsruhe Institute of Technology develop tomorrow's battery materials
Cabot Corporation Acquires Assets Of Superior MicroPowders, LLC
Investment for a new Global Innovation Center at DyStar Nanjing Site
H.B. Fuller Adds Thomas W. Handley to Board of Directors
Tyco Thermal Controls became Pentair Thermal Management
Category:Pharmaceutical_companies_of_Belgium

3D printing approaches atomic dimensions - A new electrochemical technique makes the production of complex metallic objects at the nanoscale possible
Bruker AXS Announces Acquisition of Hand-held XRF Company
New European Chemicals Agency starts operations as REACH enters into force

Chemists develop new method for water splitting - Photocatalytic process enables water to be activated
Board change at The BOC Group plc - Rebecca McDonald appointed non-executive director
